On Feb. 21, 2020, the U.S. Food and Drug Administration (FDA) approved NEXLETOL (bempedoic acid) tablet, an oral, once-daily, non-statin LDL-cholesterol lowering medicine delevoped by Esperion.

In 2004, Pfizer acquired Esperion for $1.3 billion, but two years later terminated the company. In 2008, Dr. Roger Newton acquired the rights to Esperion from Pfizer and reestablished the company in Ann Arbor, Michigan.